Acorda Therapeutics, Inc.
) continues to progress with its pipeline with the company
enrolling the first patient in a phase Ib single-infusion study
being conducted with glial growth factor 2 (GGF2). The study is
being conducted in patients with heart failure. Three doses of
GGF2 will be evaluated along with efficacy outcomes.
Acorda has been looking to expand its pipeline and reduce its
dependence on lead product, Ampyra, which is approved for the
improvement of walking in multiple sclerosis patients. Apart from
studying Ampyra for additional indications like cerebral palsy
and post-stroke deficits (phase IIb/III study to commence in the
second quarter of 2014), Acorda is evaluating other candidates
like rHIgM22 (multiple sclerosis - phase I ongoing) and
In late Sep 2013, Acorda started enrolling patients in a phase
II study being conducted with AC105. The double-blind,
randomized, placebo controlled study is being conducted in
patients with traumatic spinal cord injury (SCI). AC105's safety
and efficacy will be evaluated in this study which will have many
exploratory efficacy measures.
Acorda is also looking towards in-licensing deals and
acquisitions to expand its pipeline. In Dec 2012, Acorda acquired
Neuronex and added diazepam nasal spray (management of seizure in
certain epilepsy patients) to its pipeline. Further, in Jul 2013,
Acorda acquired NGX-1998, a phase III ready product for treating
patients suffering neuropathic pain, and Quenteza, an approved
product for the treatment of postherpetic neuralgia.
Acorda currently carries a Zacks Rank #3 (Hold). At present,
) look attractive. While Actelion and Isis Pharma are Zacks Rank
#1 (Strong Buy) stocks, Agenus is a Zacks Rank #2 (Buy)
ACORDA THERAPT (ACOR): Free Stock Analysis
AGENUS INC (AGEN): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis
To read this article on Zacks.com click here.